Abbott (ABT) Stock Looks Below Fair Value After Business Reshaping

Abbott Laboratories has had a mixed run in 2026, with the share price down year to date despite a modest recent bounce. This puts a spotlight on whether today's valuation is still grounded in the cash the business can generate. With fresh product launches and a planned nutrition spin off reshaping the profile of the group, the key issue is how those moves translate into long term cash flows that can support the current price.

• The stock is down about 17.0% year to date, which puts pressure on investors to decide whether the current level still reflects the stream of cash flows Abbott can produce over time.
• Plans to separate the Nutrition division into a stand alone public company, alongside new diagnostics offerings such as next generation cancer and screening tests, may support a different mix and timing of future cash flows across the remaining operations.
• If you'd rather focus on earnings, this one's for you. See why Abbott Laboratories's 38.1x P/E tells a different valuation story.

The issue now is whether Abbott Laboratories' recent share price, after this year to date decline and business reshaping, is justified by the cash flows implied by its intrinsic value under the Discounted Cash Flow (DCF) approach.

If you want more than a single stock to compare with Abbott Laboratories and its cash flows, you may find a targeted screen of 29 high quality undervalued stocks helpful.

Is Abbott Laboratories Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here projects the cash Abbott Laboratories can return to shareholders based on its current and future free cash generation. Latest twelve month free cash flow sits at about $7.6b in $ terms, and the forecast path from 2027 through 2036 assumes growing free cash flows rather than a shrinking stream.

Those rising projections, combined with a two stage Free Cash Flow to Equity approach, produce an estimated intrinsic value that the model suggests is substantially above the current share price of $103.10. The nutrition spin off plan and new diagnostics offerings such as the Oncodetect colorectal cancer test help explain why the Discounted Cash Flow model is building in ongoing growth even after a tougher share price run. Find out what Abbott Laboratories could be worth using our Discounted Cash Flow (DCF) estimate.

The Abbott Laboratories Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Abbott Laboratories pick up where the DCF puzzle leaves off, by spelling out which paths for revenue growth, profitability and earnings would need to play out for the stock to be worth materially more or materially less than today's price, and they sit on the platform's Community page. Rather than a single multiple or model output, each one lays out the assumptions behind its estimate of fair value so you can compare those expectations with reported results over time.

One of the top community narratives on Abbott Laboratories: 14% undervalued

"The main thing that has to go right is that Abbott Laboratories continues to convert its medical technology pipeline into sustained sales growth and margin expansion."

Discover why this Narrative puts Abbott Laboratories at 14% undervalued.

Before acting on Abbott Laboratories' valuation, weigh who is steering the ship

Before you lean too hard on the numbers for Abbott Laboratories, it is worth asking how the people making the key decisions are rewarded, and whether those incentives line up with shareholders over time. See who runs Abbott Laboratories and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com